US10968222B2ActiveUtilityA1

2-azabicyclo hexane JAK inhibitor compound

78
Assignee: THERAVANCE BIOPHARMA R&D IP LLCPriority: Oct 29, 2018Filed: Oct 18, 2019Granted: Apr 6, 2021
Est. expiryOct 29, 2038(~12.3 yrs left)· nominal 20-yr term from priority
Inventors:Paul R. FathereeLan Jiang
A61P 27/02A61K 31/437A61K 9/0048A61K 9/0019C07D 471/04
78
PatentIndex Score
1
Cited by
96
References
15
Claims

Abstract

The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes useful for preparing the compound.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A compound of formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically-acceptable salt thereof. 
     
     
       2. A compound of formula: 
       
         
           
           
               
               
           
         
       
     
     
       3. A pharmaceutical composition comprising the compound of  claim 1 , or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier. 
     
     
       4. The pharmaceutical composition of  claim 3 , wherein the composition is suitable for application to the eye. 
     
     
       5. The pharmaceutical composition of  claim 4 , wherein the composition is suitable for intravitreal injection. 
     
     
       6. The pharmaceutical composition of  claim 5 , wherein the composition is a suspension. 
     
     
       7. The pharmaceutical composition of  claim 3 , wherein the composition is a suspension. 
     
     
       8. The pharmaceutical composition of  claim 3 , wherein the composition is a crystalline suspension. 
     
     
       9. The pharmaceutical composition of  claim 3 , wherein the composition is a sterile aqueous suspension. 
     
     
       10. The pharmaceutical composition of  claim 3 , wherein the composition is an injectable composition. 
     
     
       11. The pharmaceutical composition of  claim 3 , wherein the composition is suitable for injection into the eye. 
     
     
       12. The pharmaceutical composition of  claim 3 , wherein the composition contains from 0.01 to 95% by weight of the compound of formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically-acceptable salt thereof. 
     
     
       13. The pharmaceutical composition of  claim 3 , wherein the composition contains from 0.05 to 30% by weight of the compound of formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically-acceptable salt thereof. 
     
     
       14. The pharmaceutical composition of  claim 3 , wherein the composition contains from 0.1 to 10% by weight of the compound of formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically-acceptable salt thereof. 
     
     
       15. The pharmaceutical composition of  claim 3 , wherein the composition is packaged as a unit dosage form.

Join the waitlist — get patent alerts

Track US10968222B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.